BMGF

NIIMBL Announces $1.7M from the Global Health Fund for 3 New Vaccine Manufacturing Projects

Retrieved on: 
Tuesday, February 28, 2023
BMGF, Messenger, Government, NIIMBL, Vaccine, Bill & Melinda Gates Foundation, GHF

These projects were selected to best align with key focus areas identified by NIIMBL and the Bill and Melinda Gates Foundation (BMGF) to address industry needs.

Key Points: 
  • These projects were selected to best align with key focus areas identified by NIIMBL and the Bill and Melinda Gates Foundation (BMGF) to address industry needs.
  • The Global Health Fund was established by NIIMBL with funding contributed by BMGF to develop and implement innovative technologies for vaccine and biological manufacturing that will accelerate development timelines and lower the cost of manufacturing, all in furtherance of BMGF's charitable objectives.
  • "The recent pandemic highlighted several needs for vaccine development and manufacturing across multiple potential vaccine targets.
  • NIIMBL has awarded approximately 142 technical, workforce development, and Global Health Fund projects through the Project Call process with a total project investment of over $111M since 2017 when the Institute launched.

SK bioscience Appoints New Executives to Accelerate New Growth Strategies

Retrieved on: 
Friday, January 20, 2023
Global Health, Good, CGT, Hay Group Global R&D Center for Strategy Execution, University, University of California, Berkeley, INSEAD, Drug, Sanofi Pasteur, BMGF, SK, CGMP, Health, Protein Sciences, Certification, M&A, Molecular biology, COVID-19, Bachelor of Arts, Growth, Gilead Sciences, Process, Akwa Ibom State Association of Nigeria, USA Inc., R, Eastern University, Good manufacturing practice, Pennsylvania State University, Bill, Doctor of Philosophy, Fine chemical, Medical device, Biochemistry, Science

Dr. Kensinger is an expert who has been dedicated to biopharmaceutical R&D, working at global companies for more than 20 years.

Key Points: 
  • Dr. Kensinger is an expert who has been dedicated to biopharmaceutical R&D, working at global companies for more than 20 years.
  • SK bioscience additionally recruited Kenneth Lee, former Head of Commercial Division, Americas of GenScript Probio, as Vice President of Biologic Business Development Department at R&D Center in Pangyo, South Korea.
  • Mr. Lee will be in charge of developing new biopharmaceutical-driven strategies beyond the vaccine business including a Cellular & Gene Therapy (CGT) field.
  • Jaeyong Ahn, CEO of SK bioscience said, "Now is the time for advancing beyond Korea to the global market based on our accumulated capabilities.

SK bioscience Appoints New Executives towards Global Business Growth

Retrieved on: 
Friday, October 21, 2022
Biochemistry, Bill, Doctor of Philosophy, Sanofi Pasteur, Therapy, Growth, CEPI, Akwa Ibom State Association of Nigeria, USA Inc., BMGF, Regulation of tobacco by the U.S. Food and Drug Administration, Electrical engineering, Biotechnology, HQ, BMS, OGD, Investment, VAX, Bristol Myers Squibb, University, Infection, Food, Epidemic, Coalition for Epidemic Preparedness Innovations, Company, Bill & Melinda Gates Foundation, Health, Industry, CDMO, SK Group, Plasma protein binding, CEO, Research, Virginia Tech, State university system, Head, Global Health, Coalition, Electricity, FDA, COVID-19, Pharmaceutical industry, Fine chemical, Pfizer, Microbiology

SK bioscience is accelerating its entry into the U.S. with the appointment of Dr. Harry Kleanthous.

Key Points: 
  • SK bioscience is accelerating its entry into the U.S. with the appointment of Dr. Harry Kleanthous.
  • The Company earlier appointed Dr. Hun Kim, Chief Technical Officer at SK bioscience, as Chief Executive Officer of SK bioscience USA, Inc., a new entity that will be established early next year.
  • The headquarters of SK bioscience USA, Inc. will be located in Boston, a vibrant center of biotechnology, large biopharma, and academia ecosystem.
  • SK bioscience is a global innovative vaccine and biotech company, committed to global pandemic preparedness in vaccine development and manufacturing for more equitable access.

Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

Retrieved on: 
Sunday, October 2, 2022
EUA, Indonesian Ulema Council, Food, UNICEF, COVID-19, World, G20, World Health Organization, Vaccination, Pharmacy, PEHA, Certification, Laboratory, Bio Farma, Vaccine, Public health, EUL, BMGF, PATH, Emergency Use Authorization, WHO, OPV, IDX, Bill & Melinda Gates Foundation, Oral polio vaccine AIDS hypothesis, Animal, Pharmaceutical industry, Radical honesty

BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.

Key Points: 
  • BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.
  • Under the contract, Bio Farma will export its oral polio vaccines based on purchase requests from UNICEF via multilateral contract agreement for the years 2022 & 23.
  • Honesti Basyir, President Director of Bio Farma, said, "UNICEF procures nOPV2 under a multilateral supply agreement as part of a global effort to prevent spread of the polio disease.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like the Bill and Melinda Gates Foundation (BMGF), the PATH, and the WHO.

Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines

Retrieved on: 
Sunday, September 11, 2022
Medical school, Congo, Virus, World, Emergency, Certification, Laboratory, EUL, Ministry of Law and Human Rights, COVAX, Communication, EUA, Food, UNICEF, Child, BMGF, Directorate, Pentavalent vaccine, Bio, DGIP, Ageing, Bill & Melinda Gates Foundation, Patent, COVID-19, Faculty, Hearing, Ministry of Law, Udayana University, Emergency Use Authorization, Vaccine, Public health, WHO, Oral polio vaccine AIDS hypothesis, Baylor College of Medicine, Intellectual property, World Health Organization, Democratic republic, Bio Farma, Representative, House, PATH, Documentation, Pharmaceutical industry, Medicine, Radical honesty

After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.

Key Points: 
  • After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.
  • All Covid-19 vaccines made by Bio Farma, including the primary series vaccines, booster vaccines and vaccines for children, will be labelled IndoVac.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like Bill and Melinda Gates Foundation (BMGF), PATH and the WHO.
  • Bio Farma has since become the main supplier of polio vaccines in the world, and currently contributes 67 percent to the global supply of polio vaccines.

Efficacy Testing Market worth $423 million by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, July 19, 2022
Knowledge, Ammonium, Research, Method, SGS, Conditional sentence, Intertek, Disease, Industry, Awareness, Alcohol, Cell, CAGR, Thermal analysis, Cosmetics, Critical care, Wuxi, LLC, GEM, Hospital, SME, Bill & Melinda Gates Foundation, Charles River Laboratories, Element, Organization, COVID-19, Validation, Government agency, Cros, Growth, Composition, Wellcome Trust, Intelligence, BMGF, Government, EPA, Cleaning validation, Stability testing, Bottled water, Pharmaceutical industry, Fine chemical, Marketing, Assay, Chlorine, Lucideon

Based on service type, the market is segmented into antimicrobial/preservative efficacy testing (AET/PET) and disinfectant efficacy testing.

Key Points: 
  • Based on service type, the market is segmented into antimicrobial/preservative efficacy testing (AET/PET) and disinfectant efficacy testing.
  • In 2021, the disinfectant efficacy testing segment accounted for the largest share of market.
  • The disinfectant efficacy testing segment is also expected to register the highest CAGR of 7.6% during the forecast period.
  • The efficacy testing market, by application, is segmented into pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications.

Hyperfine Reports Preliminary Unaudited 2021 Revenue and Swoop® System Installations

Retrieved on: 
Monday, January 10, 2022
Depreciation, Traction, High-dependency unit, Growth, MRI, Security (finance), Magnetic resonance imaging, Humanitarian use licenses, Patient, Income, Hospital, Bill & Melinda Gates Foundation, Marketing, Sale, U.S. Securities and Exchange Commission, GAAP, Partnership, Review, Time, Research, R, Paola Lattus, Private Securities Litigation Reform Act, Software, Nasdaq, Technology, Mission statement, RTA, COVID-19, FDA, Bill, BMGF, Medical imaging, Risk management, Hyperfine structure, Swoop

Hyperfines revenue for the years ended December 31, 2021, and 2020 is derived from commercial sales and RTA sales.

Key Points: 
  • Hyperfines revenue for the years ended December 31, 2021, and 2020 is derived from commercial sales and RTA sales.
  • Grant fulfillment installations consist of shipments of Swoop units to hospitals and other clinical facilities designated by the Bill & Melinda Gates Foundation (BMGF).
  • Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the worlds first FDA-cleared portable MRI system.
  • In certain cases, Hyperfine has provided expected ranges, rather than specific amounts, because these results are preliminary and subject to change.

Deepspatial Inc. Partners with IPE Global to Provide its Technology in the Government Sector

Retrieved on: 
Tuesday, October 5, 2021
Software, Technology, Other Technology, Data Management, Software as a service, Technology, Mastercard Foundation, UNICEF, News, Lists of countries and territories, KfW, Partnership, Artificial intelligence, Information and communications technology, Instagram, Development, Risk, World Bank, Solution, IPE Global Limited, Person, Sale, Workforce, CSE, EC, BMGF, LinkedIn, AI, Communication, UNDP, DSAI, Twitter, CEO, THE, JICA, Company, IPE, GTZ, World Bank Group, Intelligence, CIFF, USAID, Forward, Government, THIS, ADB, Industry, DANIDA, Security (finance), Deepspatial Inc., IPE Global, DEEPSPATIAL INC., IPE GLOBAL

Deepspatial Inc. (CSE:DSAI) (OTCQB:DSAIF) (Deepspatial or the Company) is pleased to announce a partnership with IPE Global Limited (IPE Global) to provide its Geospatial Artificial Intelligence (AI) (patent pending) solutions to IPE Globals clients throughout government and private sectors.

Key Points: 
  • Deepspatial Inc. (CSE:DSAI) (OTCQB:DSAIF) (Deepspatial or the Company) is pleased to announce a partnership with IPE Global Limited (IPE Global) to provide its Geospatial Artificial Intelligence (AI) (patent pending) solutions to IPE Globals clients throughout government and private sectors.
  • IPE Global will be leveraging Deepspatials technology to assist their global client base in addition to working together towards jointly proposing their solutions to specific markets and clients identified by IPE Global.
  • IPE Global Limited is a leading international development consulting group, providing Information and Communication Technology solutions for development and sustainable growth in developing countries.
  • Over the last 20 years, IPE Global has successfully implemented 800 multi-sectoral projects in over 100 countries, across 5 major continents.